Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: A study from the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, Beckerich F, Suarez F, Chevallier P, Nguyen-Quoc S, Ledoux MP, Clement L, Hicheri Y, Guillerm G, Cornillon J, Contentin N, Carre M, Maillard N, Mercier M, Mohty M, Beguin Y, Bourhis JH, Charbonnier A, Dauriac C, Bay JO, Blaise D, Deconinck E, Jubert C, Raus N, Peffault de Latour R, Dhedin N.

Am J Hematol. 2018 Mar;93(3):416-423. doi: 10.1002/ajh.25004. Epub 2018 Jan 8.

PMID:
29226497
2.

Histologic analysis has a prognostical value in colorectal biopsies assessed for suspicion of graft-versus-host disease.

Sauvestre F, Belleannée G, Bréal C, Mohr C, Fong HI, Cossin S, Tabrizi R, Milpied N, Vigouroux S, Goussot JF, Marty M.

Virchows Arch. 2018 Feb;472(2):213-220. doi: 10.1007/s00428-017-2272-2. Epub 2017 Nov 22.

PMID:
29167990
3.

Reactive or proactive? Age differences in the use of affective regulation strategies.

Le Vigouroux S, Pavani JB, Dauvier B, Kop JL, Congard A.

Psychol Aging. 2017 Nov;32(7):621-627. doi: 10.1037/pag0000197. Epub 2017 Oct 5.

PMID:
28981304
4.

Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT.

Baron F, Ruggeri A, Beohou E, Labopin M, Mohty M, Sanz J, Vigouroux S, Furst S, Bosi A, Chevallier P, Cornelissen JJ, Michallet M, Sierra J, Karakasis D, Savani BN, Gluckman E, Nagler A.

J Intern Med. 2018 Feb;283(2):178-189. doi: 10.1111/joim.12696. Epub 2017 Nov 6.

PMID:
28977716
5.

Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, Peffault de Latour R, Marçais A, Bulabois CE, Bay JO, Chantepie S, Deconinck E, Daguindau E, Contentin N, Yakoub-Agha I, Cornillon J, Mercier M, Turlure P, Charbonnier A, Rorhlich PS, N'Guyen S, Maillard N, Marchand T, Mohty M, Chevallier P; Société Francophone de Greffe de Moelle et de Thérapie Cellulaire.

Ann Oncol. 2017 Sep 1;28(9):2191-2198. doi: 10.1093/annonc/mdx274.

PMID:
28911060
6.

Clinical impact of NK-cell reconstitution after reduced intensity conditioned unrelated cord blood transplantation in patients with acute myeloid leukemia: analysis of a prospective phase II multicenter trial on behalf of the Société Française de Greffe de Moelle Osseuse et Thérapie Cellulaire and Eurocord.

Nguyen S, Achour A, Souchet L, Vigouroux S, Chevallier P, Furst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Francois S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Lejeune J, Béziat V, Rocha V, Rio B, Chevret S, Vieillard V.

Bone Marrow Transplant. 2017 Oct;52(10):1428-1435. doi: 10.1038/bmt.2017.122. Epub 2017 Jun 26.

PMID:
28650455
7.

Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation.

Gros FX, Cazaubiel T, Forcade E, Lechevalier N, Leguay T, Servant V, Tabrizi R, Clement L, Dumas PY, Bidet A, Pigneux A, Vigouroux S, Milpied N.

Bone Marrow Transplant. 2017 Jul;52(7):1047-1048. doi: 10.1038/bmt.2017.78. Epub 2017 Jun 5. No abstract available.

PMID:
28581465
8.

Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Qian C, Campidelli A, Wang Y, Cai H, Venard V, Jeulin H, Dalle JH, Pochon C, D'aveni M, Bruno B, Paillard C, Vigouroux S, Jubert C, Ceballos P, Marie-Cardine A, Galambrun C, Cholle C, Clerc Urmes I, Petitpain N, De Carvalho Bittencourt M, Decot V, Reppel L, Salmon A, Clement L, Bensoussan D.

J Hematol Oncol. 2017 May 8;10(1):102. doi: 10.1186/s13045-017-0469-0.

9.

No adverse effect of granulocyte colony-stimulating factor during the peri-implantation period of an unrecognized pregnancy in a donor of peripheral blood stem cells.

Debus L, Vigouroux S, Gargallo G, Adiko F, Milpied N.

Leuk Lymphoma. 2017 Dec;58(12):2979-2980. doi: 10.1080/10428194.2017.1312389. Epub 2017 May 9. No abstract available.

PMID:
28482751
10.

Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes.

Martino R, Henseler A, van Lint M, Schaap N, Finke J, Beelen D, Vigouroux S, Alessandrino EP, Mufti GJ, Veelken JH, Bruno B, Yakoub-Agha I, Volin L, Maertens J, Or R, Leblond V, Rovira M, Kalhs P, Alvarez AF, Vitek A, Sierra J, Wagner E, Robin M, de Witte T, Kröger N.

Bone Marrow Transplant. 2017 Aug;52(8):1107-1112. doi: 10.1038/bmt.2017.19. Epub 2017 Mar 20.

PMID:
28319072
11.

Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC.

Magro L, Gauthier J, Richet M, Robin M, Nguyen S, Suarez F, Dalle JH, Fagot T, Huynh A, Rubio MT, Oumadely R, Vigouroux S, Milpied N, Delcampe A, Yakoub-Agha I.

Bone Marrow Transplant. 2017 Jun;52(6):878-882. doi: 10.1038/bmt.2017.9. Epub 2017 Feb 20.

PMID:
28218751
12.

Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.

Damaj G, Cornillon J, Bouabdallah K, Gressin R, Vigouroux S, Gastinne T, Ranchon F, Ghésquières H, Salles G, Yakoub-Agha I, Gyan E.

Bone Marrow Transplant. 2017 Jul;52(7):941-949. doi: 10.1038/bmt.2016.340. Epub 2017 Jan 23. Review.

PMID:
28112752
13.

Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT).

Poiré X, Labopin M, Maertens J, Yakoub-Agha I, Blaise D, Ifrah N, Socié G, Gedde-Dhal T, Schaap N, Cornelissen JJ, Vigouroux S, Sanz J, Michaux L, Esteve J, Mohty M, Nagler A.

J Hematol Oncol. 2017 Jan 18;10(1):20. doi: 10.1186/s13045-017-0393-3.

14.

Immune stimulation during chemotherapy increases incidence of acute graft versus host disease in acute myeloid leukemia: A study on behalf of SFGM-TC and ALFA.

Wang L, Raffoux E, Thomas X, Yakoub-Agha I, Bouhris JH, de Botton S, Michallet M, Quoc SN, Chantepie S, Deconinck E, Caillot D, Turlure P, Vigouroux S, Pigneux A, Huynh A, Malfuson JV, Loschi M, Socie G, Dombret H, de la Tour RP, Cluzeau T.

Leuk Res. 2017 Mar;54:12-16. doi: 10.1016/j.leukres.2017.01.002. Epub 2017 Jan 5.

PMID:
28088653
15.

A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD.

Socié G, Vigouroux S, Yakoub-Agha I, Bay JO, Fürst S, Bilger K, Suarez F, Michallet M, Bron D, Gard P, Medeghri Z, Lehert P, Lai C, Corn T, Vernant JP.

Blood. 2017 Feb 2;129(5):643-649. doi: 10.1182/blood-2016-09-738625. Epub 2016 Nov 29.

16.

Long-term survival and late events after allogeneic stem cell transplantation from HLA-matched siblings for acute myeloid leukemia with myeloablative compared to reduced-intensity conditioning: a report on behalf of the acute leukemia working party of European group for blood and marrow transplantation.

Shimoni A, Labopin M, Savani B, Volin L, Ehninger G, Kuball J, Bunjes D, Schaap N, Vigouroux S, Bacigalupo A, Veelken H, Sierra J, Eder M, Niederwieser D, Mohty M, Nagler A.

J Hematol Oncol. 2016 Nov 8;9(1):118.

17.

Clofarabine versus fludarabine-based reduced-intensity conditioning regimen prior to allogeneic transplantation in adults with AML/MDS.

Chevallier P, Labopin M, de La Tour RP, Lioure B, Bulabois CE, Huynh A, Blaise D, Turlure P, Daguindau E, Maillard N, Yakoub-Agha I, Guillerm G, Delage J, Contentin N, Bay JO, Beckerich F, Bourhis JH, Detrait M, Vigouroux S, François S, Legrand F, Guillaume T, Mohty M; SFGM-TC.

Cancer Med. 2016 Nov;5(11):3068-3076. doi: 10.1002/cam4.880. Epub 2016 Oct 17.

18.

Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia.

Mohty M, Malard F, Blaise D, Milpied N, Socié G, Huynh A, Reman O, Yakoub-Agha I, Furst S, Guillaume T, Tabrizi R, Vigouroux S, Peterlin P, El-Cheikh J, Moreau P, Labopin M, Chevallier P.

Haematologica. 2017 Jan;102(1):184-191. doi: 10.3324/haematol.2016.150326. Epub 2016 Aug 25.

19.

Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.

Rabian F, Porcher R, Sicre de Fontbrune F, Lioure B, Laplace A, Nguyen S, Tabrizi R, Vigouroux S, Tomowiak C, Maillard N, Suarez F, Delage J, Peffault de Latour R, Socié G; French Society of Bone Marrow Transplantation and Cell Therapy.

Biol Blood Marrow Transplant. 2016 Sep;22(9):1721-1724. doi: 10.1016/j.bbmt.2016.05.022. Epub 2016 May 28.

20.

Saprochaete clavata invasive infection in a patient with severe aplastic anemia: Efficacy of voriconazole and liposomal amphotericin B with adjuvant granulocyte transfusions before neutrophil recovery following allogeneic bone marrow transplantation.

Favre S, Rougeron A, Levoir L, Pérard B, Milpied N, Accoceberry I, Gabriel F, Vigouroux S.

Med Mycol Case Rep. 2016 Mar 8;11:21-3. doi: 10.1016/j.mmcr.2016.03.001. eCollection 2016 Mar.

21.

Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the French Society of Bone Marrow Transplantation and Cell Therapies and the EBMT Severe Aplastic Anemia Working Party.

Devillier R, Dalle JH, Kulasekararaj A, D'aveni M, Clément L, Chybicka A, Vigouroux S, Chevallier P, Koh M, Bertrand Y, Michallet M, Zecca M, Yakoub-Agha I, Cahn JY, Ljungman P, Bernard M, Loiseau P, Dubois V, Maury S, Socié G, Dufour C, Peffault de Latour R.

Haematologica. 2016 Jul;101(7):884-90. doi: 10.3324/haematol.2015.138727. Epub 2016 Apr 7.

22.

High CD3+ and CD34+ peripheral blood stem cell grafts content is associated with increased risk of graft-versus-host disease without beneficial effect on disease control after reduced-intensity conditioning allogeneic transplantation from matched unrelated donors for acute myeloid leukemia - an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Czerw T, Labopin M, Schmid C, Cornelissen JJ, Chevallier P, Blaise D, Kuball J, Vigouroux S, Garban F, Lioure B, Fegueux N, Clement L, Sandstedt A, Maertens J, Guillerm G, Bordessoule D, Mohty M, Nagler A.

Oncotarget. 2016 May 10;7(19):27255-66. doi: 10.18632/oncotarget.8463.

23.

Allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning regimen for elderly patients (60 years and older) with hematologic malignancies using unrelated donors: a retrospective study from the French society for stem cell transplantation (SFGM-TC).

El Cheikh J, Sfumato P, Sobh M, Fegueux N, Mohty M, Vigouroux S, Beguin Y, Yakoub-Agha I, Socié G, Cornillon J, Mercier M, Bay JO, Blaise D, Michallet M, Peffault de Latour R.

Haematologica. 2016 Jun;101(6):e262-5. doi: 10.3324/haematol.2015.139345. Epub 2016 Mar 18. No abstract available.

24.

Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis.

Nagler A, Savani BN, Labopin M, Polge E, Passweg J, Finke J, Kyrcz-Krzemien S, Volin L, Anagnostopoulos A, Aljurf M, Beelen DW, Vigouroux S, Milpied N, Suarez F, Mohty M.

Lancet Haematol. 2015 Sep;2(9):e384-92. doi: 10.1016/S2352-3026(15)00146-5. Epub 2015 Aug 24.

PMID:
26685771
25.

Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT.

Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT.

Bone Marrow Transplant. 2016 Mar;51(3):351-7. doi: 10.1038/bmt.2015.278. Epub 2015 Nov 30.

PMID:
26618548
26.

Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Mamez AC, Lévy V, Chevallier P, Blaise D, Vigouroux S, Xhaard A, Fegueux N, Contentin N, Beguin Y, Ifrah N, Bulabois CE, Suarez F, Yakoub-Agha I, Turlure P, Deconink E, Lamy T, Cahn JY, Huynh A, Maury S, Fornecker LM, Ouzegdouh M, Bay JO, Guillerm G, Maillard N, Michallet M, Malfuson JV, Bourhis JH, Rialland F, Oumedaly R, Jubert C, Leblond V, Boubaya M, Mohty M, Nguyen S.

Bone Marrow Transplant. 2016 Mar;51(3):358-64. doi: 10.1038/bmt.2015.280. Epub 2015 Nov 23.

PMID:
26595076
27.

Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.

Savani BN, Labopin M, Blaise D, Niederwieser D, Ciceri F, Ganser A, Arnold R, Afanasyev B, Vigouroux S, Milpied N, Hallek M, Cornelissen JJ, Schwerdtfeger R, Polge E, Baron F, Esteve J, Gorin NC, Schmid C, Giebel S, Mohty M, Nagler A.

Haematologica. 2016 Feb;101(2):256-62. doi: 10.3324/haematol.2015.135699. Epub 2015 Nov 12.

28.

In patients older than 55 years with AML in first CR, should we search for a matched unrelated donor when an old sibling donor is available?

Peffault de Latour R, Labopin M, Cornelissen J, Vigouroux S, Craddock C, Blaise D, Huyn A, Vindelov L, Maertens J, Chevallier P, Fegueux N, Socié G, Cahn JY, Petersen E, Schouten H, Lioure B, Russell N, Corral LL, Ciceri F, Nagler A, Mohty M; Acute Leukemia Working Party of EBMT.

Bone Marrow Transplant. 2015 Nov;50(11):1411-5. doi: 10.1038/bmt.2015.180. Epub 2015 Sep 14.

PMID:
26367237
29.

Sirolimus-related anal ulceration in a female patient after allogeneic stem cell transplantation.

Haïk L, Beylot-Barry M, Vigouroux S, Tabrizi R, Milpied N.

Bone Marrow Transplant. 2016 Jan;51(1):132-3. doi: 10.1038/bmt.2015.198. Epub 2015 Sep 14. No abstract available.

PMID:
26367228
30.

Management of Myelodysplastic Syndrome Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation: A Study by the French Society of Bone Marrow Transplantation and Cell Therapies.

Guièze R, Damaj G, Pereira B, Robin M, Chevallier P, Michallet M, Vigouroux S, Beguin Y, Blaise D, El Cheikh J, Roos-Weil D, Thiebaut A, Rohrlich PS, Huynh A, Cornillon J, Contentin N, Suarez F, Lioure B, Mohty M, Maillard N, Clement L, François S, Guillerm G, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2016 Feb;22(2):240-247. doi: 10.1016/j.bbmt.2015.07.037. Epub 2015 Aug 6.

31.

Trichosporon faecale invasive infection in a patient with severe aplastic anemia: Efficacy of voriconazole and liposomal amphotericin B before neutrophil recovery.

Pérard B, Rougeron A, Favre S, Accoceberry I, Vigouroux S, Mohr C, Milpied N.

Med Mycol Case Rep. 2015 Jul 2;9:12-4. doi: 10.1016/j.mmcr.2015.06.003. eCollection 2015 Sep.

32.

The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Rubio MT, Labopin M, Blaise D, Socié G, Contreras RR, Chevallier P, Sanz MA, Vigouroux S, Huynh A, Shimoni A, Bulabois CE, Caminos N, López-Corral L, Nagler A, Mohty M.

Haematologica. 2015 May;100(5):683-9. doi: 10.3324/haematol.2014.119339. Epub 2015 Mar 13.

33.

Contribution of Revised International Prognostic Scoring System Cytogenetics to Predict Outcome After Allogeneic Stem Cell Transplantation for Myelodysplastic Syndromes: A Study From the French Society of Bone Marrow Transplantation and Cellular Therapy.

Gauthier J, Damaj G, Langlois C, Robin M, Michallet M, Chevallier P, Beguin Y, N'guyen S, Bories P, Blaise D, Cornillon J, Clavert A, Mohty M, Huynh A, Thiébaut-Bertrand A, Vigouroux S, Duhamel A, Yakoub-Agha I.

Transplantation. 2015 Aug;99(8):1672-80. doi: 10.1097/TP.0000000000000649.

PMID:
25769079
34.

HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM.

Robin M, Porcher R, Adès L, Raffoux E, Michallet M, François S, Cahn JY, Delmer A, Wattel E, Vigouroux S, Bay JO, Cornillon J, Huynh A, Nguyen S, Rubio MT, Vincent L, Maillard N, Charbonnier A, de Latour RP, Reman O, Dombret H, Fenaux P, Socié G.

Leukemia. 2015 Jul;29(7):1496-501. doi: 10.1038/leu.2015.37. Epub 2015 Feb 13.

PMID:
25676424
35.

Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.

Calmettes C, Vigouroux S, Labopin M, Tabrizi R, Turlure P, Lafarge X, Marit G, Pigneux A, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Mohr C, Lascaux A, Dumas PY, Dimicoli-Salazar S, Saint-Lézer A, Milpied N.

Biol Blood Marrow Transplant. 2015 May;21(5):860-5. doi: 10.1016/j.bbmt.2015.01.016. Epub 2015 Jan 21.

36.

Transient grades 3 to 4 acute hepatitis is a common complication of rabbit antithymocyte globulin (thymoglobulin) administered before allogeneic stem cell transplantation.

Médiavilla C, Vigouroux S, Tabrizi R, Pigneux A, Duclos C, Mohr C, Robles M, Milpied N.

Biol Blood Marrow Transplant. 2015 Apr;21(4):661-5. doi: 10.1016/j.bbmt.2014.12.014. Epub 2014 Dec 20.

37.

Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial.

Rio B, Chevret S, Vigouroux S, Chevallier P, Fürst S, Sirvent A, Bay JO, Socié G, Ceballos P, Huynh A, Cornillon J, Françoise S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Gluckman E, Ruggeri A, Buzyn A, Nguyen S, Simon T, Milpied N, Rocha V; Société Française de Greffe de Moelle et de Thérapie Cellulaire and Eurocord.

Biol Blood Marrow Transplant. 2015 Mar;21(3):445-53. doi: 10.1016/j.bbmt.2014.11.009. Epub 2014 Nov 18.

38.

Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

Detrait MY, Morisset S, Peffault de Latour R, Yakoub-Agha I, Crocchiolo R, Tabrizi R, Bay JO, Chevalier P, Barraco F, Raus N, Vigouroux S, Magro L, Mohty M, Milpied N, Blaise D, Socié G, Michallet M.

Bone Marrow Transplant. 2015 Feb;50(2):253-8. doi: 10.1038/bmt.2014.244. Epub 2014 Nov 3.

PMID:
25365068
39.

90Y-ibritumomab tiuxetan, fludarabine, busulfan and antithymocyte globulin reduced-intensity allogeneic transplant conditioning for patients with advanced and high-risk B-cell lymphomas.

Bouabdallah K, Furst S, Asselineau J, Chevalier P, Tournilhac O, Ceballos P, Vigouroux S, Tabrizi R, Doussau A, Bouabdallah R, Mohty M, Le Gouill S, Blaise D, Milpied N.

Ann Oncol. 2015 Jan;26(1):193-8. doi: 10.1093/annonc/mdu503. Epub 2014 Oct 30.

PMID:
25361987
40.

Reduced-toxicity conditioning with fludarabine, once-daily intravenous busulfan, and antithymocyte globulins prior to allogeneic stem cell transplantation: results of a multicenter prospective phase 2 trial.

Mohty M, Malard F, Blaise D, Milpied N, Furst S, Tabrizi R, Guillaume T, Vigouroux S, El-Cheikh J, Delaunay J, Le Gouill S, Moreau P, Labopin M, Chevallier P.

Cancer. 2015 Feb 15;121(4):562-9. doi: 10.1002/cncr.29087. Epub 2014 Oct 3. Erratum in: Cancer. 2015 Mar 1;121(5):800.

41.

Comparison of umbilical cord blood allogeneic stem cell transplantation vs. auto-SCT for adult acute myeloid leukemia patients in second complete remission at transplant: a retrospective study on behalf of the SFGM-TC.

Chevallier P, Labopin M, Socie G, Rubio MT, Blaise D, Vigouroux S, Huynh A, Michallet M, Bay JO, Maury S, Yakoub-Agha I, Fegueux N, Deconinck E, Contentin N, Maillard N, Bulabois CE, Francois S, Oumedaly R, Raus N, Mohty M.

Eur J Haematol. 2015 May;94(5):449-55. doi: 10.1111/ejh.12451. Epub 2014 Oct 13.

PMID:
25238651
42.

Sequential treatment for allogeneic hematopoietic stem cell transplantation in Fanconi anemia with acute myeloid leukemia.

Talbot A, Peffault de Latour R, Raffoux E, Buchbinder N, Vigouroux S, Milpied N, Leblanc T, Soulier J, Michallet M, Socié G.

Haematologica. 2014 Oct;99(10):e199-200. doi: 10.3324/haematol.2013.098954. Epub 2014 Aug 1. No abstract available.

43.

Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.

Chevallier P, Labopin M, Socié G, Tabrizi R, Furst S, Lioure B, Guillaume T, Delaunay J, de La Tour RP, Vigouroux S, El-Cheikh J, Blaise D, Michallet M, Bilger K, Milpied N, Moreau P, Mohty M.

Haematologica. 2014 Sep;99(9):1486-91. doi: 10.3324/haematol.2014.108563. Epub 2014 Jun 20.

44.

Upfront allogeneic stem cell transplantation after reduced-intensity/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire.

Damaj G, Mohty M, Robin M, Michallet M, Chevallier P, Beguin Y, Nguyen S, Bories P, Blaise D, Maillard N, Rubio MT, Fegueux N, Cornillon J, Clavert A, Huynh A, Adès L, Thiébaut-Bertrand A, Hermine O, Vigouroux S, Fenaux P, Duhamel A, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2014 Sep;20(9):1349-55. doi: 10.1016/j.bbmt.2014.05.010. Epub 2014 May 14.

45.

Regulatory T-cell depletion in donor lymphocyte infusions for haematological malignancies: long-term outcomes from a prospective study.

Maury S, Redjoul R, Cabanne L, Vigouroux S, Legros L, Cohen JL.

Br J Haematol. 2014 Aug;166(3):452-5. doi: 10.1111/bjh.12856. Epub 2014 Mar 25. No abstract available.

PMID:
24661112
46.

Allo-SCT for  Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC).

Cahu X, Chevallier P, Clavert A, Suarez F, Michallet M, Vincent L, Vigouroux S, Blaise D, Mariette C, Bilger K, Robin M, Yakoub-Agha I, Peffault de Latour R, Mohty M.

Bone Marrow Transplant. 2014 Jun;49(6):756-60. doi: 10.1038/bmt.2014.31. Epub 2014 Mar 10.

PMID:
24614840
47.

T-cell therapy using a bank of EBV-specific cytotoxic T cells: lessons from a phase I/II feasibility and safety study.

Gallot G, Vollant S, Saïagh S, Clémenceau B, Vivien R, Cerato E, Bignon JD, Ferrand C, Jaccard A, Vigouroux S, Choquet S, Dalle JH, Frachon I, Bruno B, Mothy M, Mechinaud F, Leblond V, Milpied N, Vié H.

J Immunother. 2014 Apr;37(3):170-9. doi: 10.1097/CJI.0000000000000031.

PMID:
24598452
48.

Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy.

Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I.

Biol Blood Marrow Transplant. 2014 May;20(5):646-54. doi: 10.1016/j.bbmt.2014.01.016. Epub 2014 Jan 22.

49.

Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Baron F, Labopin M, Blaise D, Lopez-Corral L, Vigouroux S, Craddock C, Attal M, Jindra P, Goker H, Socié G, Chevallier P, Browne P, Sandstedt A, Duarte RF, Nagler A, Mohty M.

Bone Marrow Transplant. 2014 Mar;49(3):389-96. doi: 10.1038/bmt.2013.204. Epub 2014 Jan 13.

PMID:
24419525
50.

Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response.

Robles M, Vigouroux S, Tabrizi R, Bouabdallah K, Dilhuydy MS, Parrens M, Leguay T, Pigneux A, Dumas PY, Lascaux A, Duclos C, Marit G, Milpied N.

Bone Marrow Transplant. 2013 Nov;48(11):1484-5. doi: 10.1038/bmt.2013.86. Epub 2013 Jun 3. No abstract available.

PMID:
23727750

Supplemental Content

Loading ...
Support Center